Amin N.a· Thompson J.b· Goloubeva O.c· Witek M.d· Taylor R.J.b· Wolf J.S.b· Moyer K.b· Mehra R.d· Hatten K.M.b

Author affiliations

aUniversity of Maryland, School of Medicine, Baltimore, MD, USA
bDepartment of Otorhinolaryngology – Head and Neck Surgery, Univeristy of Maryland, School of Medicine, Batimore, MD, USA
cDepartment of Epidemiology and Public Health, University of Maryland, School of Medicine, Baltimore, MD, USA
dMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, School of Medicine, Baltimore, MD, USA

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: January 11, 2022
Accepted: April 17, 2022
Published online: September 06, 2022

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 1

ISSN: 0301-1569 (Print)
eISSN: 1423-0275 (Online)

For additional information: https://www.karger.com/ORL

Abstract

Introduction: The study objective was to identify practice patterns in oropharyngeal cancer management from 2010 to 2016 among human papillomavirus (HPV)-associated and non-HPV-associated oropharyngeal squamous-cell carcinoma (OPSCC) patients. Methods: The National Cancer Database was utilized to identify OPSCC patients from 2010 to 2016. Frequency distributions and multivariable analyses were generated to identify practice patterns and predictors of treatment modality. Results: A total of 35,956 patients with nonmetastatic OPSCC were included. HPV status was not associated with a treatment modality preference. At academic centers, the proportion of HPV-associated OPSCC patients versus non-HPV-associated OPSCC patients undergoing surgical management was similar (35.7%; 35.9%). Community cancer programs treated patients less often surgically but with no significant treatment preference based on HPV status. Within each facility type, HPV status was not a predictor of surgical or nonsurgical management. Conclusion: HPV association does not appear to significantly influence treatment modality preference among OPSCC patients. The proportion of OPSCC patients undergoing surgical treatment declined from 2010 to 2016.

© 2022 S. Karger AG, Basel

References Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24–35. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015 Oct 10;33(29):3235–42. Lydiatt W, O’Sullivan B, Patel S. Major changes in head and neck staging for 2018. Am Soc Clin Oncol Educ Book. 2018 May 23;38:505–14. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;37(5):1–9. Lassen P, Eriksen JG, Krogdahl A, Therkildsen MH, Ulhøi BP, Overgaard M, et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol. 2011 Jul 1;100(1):49–55. Rischin D, Young RJ, Fisher R, Fox SB, Le Q-T, Peters LJ, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010 Sep 20;28(27):4142–8. Sturgis EM, Ang KK. The epidemic of HVP-associated oropharyngeal cancer is here: is it time to change our treatment paradigms?J Natl Compr Canc Netw. 2011 Jun 1;9(6):665–73. De Felice F, Tombolini V, Valentini V, de Vincentiis M, Mezi S, Brugnoletti O, et al. Advances in the management of HPV-related oropharyngeal cancer. J Oncol. 2019;2019:9173729. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999 Dec 15;91(24):2081–6. Chen AY, Zhu J, Fedewa S. Temporal trends in oropharyngeal cancer treatment and survival: 1998–2009. Laryngoscope. 2014 Jan 5;124(1):131–8. Cracchiolo JR, Roman BR, Kutler DI, Kuhel WI, Cohen MA. Adoption of transoral robotic surgery compared with other surgical modalities for treatment of oropharyngeal squamous cell carcinoma. J Surg Oncol. 2016 Sep 15;114(4):405–11. Gal TJ, Slezak JA, Kejner AE, Chen Q, Huang B. Treatment trends in oropharyngeal carcinoma: surgical technology meets the epidemic. Oral Oncol. 2019 Oct;97:62–8. Liederbach E, Lewis CM, Yao K, Brockstein BE, Wang CH, Lutfi W, et al. A contemporary analysis of surgical trends in the treatment of squamous cell carcinoma of the oropharynx from 1998 to 2012: a report from the National Cancer Database. Ann Surg Oncol. 2015 Dec 17;22(13):4422–31. Cracchiolo JR, Baxi SS, Morris LG, Ganly I, Patel SG, Cohen MA, et al. Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. Cancer. 2016 May 15;122(10):1523–32. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011 Nov 10;29(32):4294–301. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582–9. Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, et al. Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019 Apr 25;37(18):1578–89. Bigelow EO, Seiwert TY, Fakhry C. Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: current state and future directions. Oral Oncol. 2020 Jun;105:104652. Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, et al. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022 Jan 10;40(2):138–49. Swisher-McClure S, Lukens JN, Aggarwal C, Ahn P, Basu D, Bauml JM, et al. A phase 2 trial of alternative volumes of oropharyngeal irradiation for de-intensification (AVOID): omission of the resected primary tumor bed after transoral robotic surgery for human papilloma virus – related squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):725–32. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019 Oct 1;20(10):1349–59. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019 Jan 5;393(10166):51–60. Zhan KY, Puram SV, Li MM, Silverman DA, Agrawal AA, Ozer E, et al. National treatment trends in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Cancer. 2020 Mar 15;126(6):1295–305. Carey RM, Fathy R, Shah RR, Rajasekaran K, Cannady SB, Newman JG, et al. Association of type of treatment facility with overall survival after a diagnosis of head and neck cancer. JAMA Netw open. 2020 Jan 3;3(1):e1919697. Eskander A, Merdad M, Irish JC, Hall SF, Groome PA, Freeman JL, et al. Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis. Head Neck. 2014 Dec;36(12):1820–34. Amin JD, Rodriggs T, Weir KA, Snider JW, Hatten KM. Prospective evaluation of swallowing symptoms in human papillomavirus-associated oropharynx cancer. Dysphagia. 2022 Feb;37(1):58–64. Goldenberg D, Begum S, Westra WH, Khan Z, Sciubba J, Pal SI, et al. Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck. 2008 Jul;30(7):898–903. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31(6):744–54. Article / Publication Details

First-Page Preview

Received: January 11, 2022
Accepted: April 17, 2022
Published online: September 06, 2022

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 1

ISSN: 0301-1569 (Print)
eISSN: 1423-0275 (Online)

For additional information: https://www.karger.com/ORL

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.